Our Partners
Remedica is a leading pharmaceutical company based in Limassol, Cyprus. Its factories have been approved by European Union Member States, including Germany, Denmark, and the UK, as well as by the Australian TGA and many other health authorities. Its products are marketed in over 100 countries (in Europe, Asia, Africa, Australasia, and South America) through a selective network of representatives and its contribution to improving world health has been recognized with the presentation of a number of awards.
Dedicated to the development, production, and sale of high quality generic pharmaceutical products, Remedica plays an important role in bringing improved healthcare at affordable prices to millions of people around the world.
In its four modern manufacturing facilities, Remedica produces a variety of pharmaceutical dosage forms, including tablets, capsules, creams, ointments, aerosols, pessaries, suppositories, liquids, and powders. These fall into a wide range of therapeutic categories, such as anticancer, antibiotics, analgesics, cardiovascular drugs, CNS agents, drugs for the GI tract, diuretics, antihistamines, antidiabetics, antiparkinsonian agents, hormones and synthetic substitutes, vitamins, cough medicines and expectorants, and many more.
In addition to its business activities, Remedica takes its global responsibility towards society very seriously and runs an extensive program of activities based on its Corporate Social Responsibility plan.
For more information please visit the official Remedica website at www.remedica.eu
Zydus Cadila is an innovative global pharmaceutical company which discovers, develops, manufactures, and markets a broad range of healthcare products. The group’s operations range from API and formulations to animal health products and cosmeceuticals. Headquartered in the city of Ahmedabad in India, the group has global operations in four continents spread across the USA, Europe, Japan, Brazil, South Africa, and twenty-five other emerging markets.
In its mission to create healthier communities around the globe, Zydus Cadila delivers wide ranging healthcare solutions and value to its customers. With over 10,000 employees worldwide, a world-class research and development centre dedicated to discovery research, and eight state-of-the-art manufacturing plants, the group is dedicated to improving people’s lives.
Zydus Cadila is one of the leading players in the Indian healthcare industry, and is currently ranked 4th domestically. It is the leading player in the cardiovascular, gastrointestinal, and women's healthcare segments. The group also has a strong presence in the respiratory, pain management, CNS, anti-infectives, oncology, neurosciences, dermatology, and nephrology segments. It has been able to maintain its overall position and market share through faster growing chronic/lifestyle segments.
For more information please visit www.zyduscadila.com
Sun Pharma is an international specialty pharmaceutical company, with a presence in thirty markets.
In branded markets, Sun Pharma’s products are prescribed in chronic therapy areas including cardiology, psychiatry, neurology, gastroenterology, diabetology, and respiratory. Sun Pharma also makes active pharmaceutical ingredients.
In India, Sun Pharma has achieved a leadership position in each of the therapy areas in which we operate, and is rated among the leading companies by key customers.
In the years since 1996, Sun Pharma has used a combination of internal growth and acquisitions to drive growth; important mergers included those with the Detroit-based Caraco Pharm Labs, ICN Hungary (now called Alkaloida Chemical Company Exclusive Group), and that with the internationally approved plants in Halol, India as well as in Bryan, Ohio, US and Cranbury, NJ, US.
Sun Pharma has also shifted work related to new molecules and drug delivery systems to a company, SPARC, which is listed on the Indian stock exchange.
In the Indian prescription market, Sun Pharma is ranked 6th by prescription share, with market share at 3.5% and a growth rate of 15%, out pacing the industry average. Adding to market share and keeping this customer focus remains a high priority area for the company.
For more information please visit www.sunpharma.com